

Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes

Fresneau, Brice; Hackshaw, A; Hawkins, D S; Paulussen, M; Anderson, J R; Judson, I; Litière, S; Dirksen, U; Lewis, I; van den Berg, H; Gaspar, N; Gelderblom, H; Whelan, J; Boddy, A V; Wheatley, K; Pignon, J P; De Vathaire, F; Le Deley, M C; Le Teuff, G

DOI:
[10.1002/pbc.26457](https://doi.org/10.1002/pbc.26457)

License:
None: All rights reserved

Document Version
Peer reviewed version

Citation for published version (Harvard):

Fresneau, B, Hackshaw, A, Hawkins, DS, Paulussen, M, Anderson, JR, Judson, I, Litière, S, Dirksen, U, Lewis, I, van den Berg, H, Gaspar, N, Gelderblom, H, Whelan, J, Boddy, AV, Wheatley, K, Pignon, JP, De Vathaire, F, Le Deley, MC & Le Teuff, G 2017, 'Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)', *Pediatric Blood & Cancer*. <https://doi.org/10.1002/pbc.26457>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This is the peer reviewed version of the following article: Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, Anderson JR, Judson I, Litière S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, and Le Teuff G. Investigating the heterogeneity of alkylating agents' efficacy and toxicity between genders: a systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study). *Pediatr Blood Cancer*. 2017, which has been published in final form at <http://dx.doi.org/10.1002/pbc.26457>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving."

Publication details confirmed 28/2/2017

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Investigating the heterogeneity of alkylating agents' efficacy and toxicity between genders: a systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)

Fresneau B, MD¹, Hackshaw A, PhD², Hawkins DS, MD³, Paulussen M, MD, PhD⁴, Anderson JR, PhD⁵, Judson I, MD, PhD⁶, Litière S, PhD⁷, Dirksen U, MD, PhD⁸, Lewis I, MD, PhD⁹, van den Berg H¹⁰, Gaspar N, MD, PhD¹, Gelderblom H, MD, PhD¹¹, Whelan J, MD, PhD¹², Boddy AV, MD, PhD¹³, Wheatley K, PhD¹⁴, Pignon JP, MD, PhD^{15,16}, De Vathaire F, PhD¹⁷, Le Deley MC, MD, PhD¹⁵, Le Teuff G, PhD^{15,16}

1: Gustave Roussy, Université Paris-Saclay, Department of Pediatric oncology, Villejuif, F-94805, France, brice.fresneau@gustaveroussy.fr

2: Cancer Research UK & UCL Cancer Trials Centre, University College London, London, a.hackshaw@ucl.ac.uk

3: Department of Pediatrics, Division of Hematology/Oncology, Seattle Children's Hospital, Fred Hutchinson, Cancer Research Center, University of Washington, Seattle, WA, United States of America, doug.hawkins@seattlechildrens.org

4: Vestische Kinder-und Jugendklinik Datteln, Witten/Herdecke University, Datteln, Germany, M.Paulussen@kinderklinik-datteln.de

5: Merck Research Laboratories – Oncology, North Wales, PA, USA, jamesanderson108@gmail.com

6: The Royal Marsden NHS Foundation Trust, London, United Kingdom, Ian.Judson@icr.ac.uk

7: Statistics department, EORTC Headquarters, Brussels, Belgium, saskia.litiere@eortc.be

8: Department of Pediatric Hematology and Oncology, University Hospital, Muenster, Germany, Uta.Dirksen@ukmuenster.de

9: Alder Hey Children's NHS Foundation Trust, Liverpool, Ian.Lewis@alderhey.nhs.uk

10: Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands, h.vandenberg@amc.uva.nl

11: Department of medical oncology, Leiden University Medical Center, The Netherlands, A.J.Gelderblom@lumc.nl

12: Cancer Medicine and Consultant Medical Oncologist, The London Sarcoma Service, University College Hospital, 1st Floor Central, 250 Euston Road, London NW1 2PG, jeremy.whelan@uclh.nhs.uk

13: Faculty of Pharmacy, University of Sydney, Sydney, Australia, alan.boddy@newcastle.ac.uk

14: Cancer Research UK, Cancer Trials Unit, University of Birmingham, Birmingham, k.wheatley@bham.ac.uk

15: Departments of Biostatistics and Epidemiology, Gustave-Roussy, Paris, France and Paris-Saclay and Paris-Sud Universities, CESP, INSERM, Villejuif, France, Jean-pierre.PIGNON@gustaveroussy.fr, Gwenael.LETEUFF@gustaveroussy.fr, Marie-Cecile.LEDELEY@gustaveroussy.fr

16: Gustave Roussy, Ligue Nationale Contre le Cancer Meta-analysis Platform, Villejuif, France

17: Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France, Florent.DEVATHAIRE@gustaveroussy.fr

* Correspondence to: Brice Fresneau, MD, Department of Pediatric oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France, Tel: +33(0)1 42 11 46 22, Fax: +33(0)1 42 11 53 28, Email: brice.fresneau@gustaveroussy.fr

Abstract word count: 250

Text word count: 2424

Text pages: 22

Tables: 3

Figures: 3

Supplementary material: 2 tables + 7 Figures

Brief running title: Alkylating agents and sex: a meta-analysis

Keywords: Sarcoma, alkylating agent, cyclophosphamide, ifosfamide, efficacy, acute toxicity, treatment-by sex interaction, systematic review, meta-analysis, individual patient data

Abbreviations

RCT	Randomized controlled trial
EFS	Event-free survival
PFS	Progression-free survival
OS	Overall survival
HR	Hazard ratio
OR	Odds ratio
95%CI	95%-confidence interval
VAC	Vincristine dactinomycin cyclophosphamide
VAI	Vincristine dactinomycin ifosfamide

66 **ABSTRACT**

67 **Background:** A marginal interaction between sex and the type of alkylating agent was
68 observed for event-free survival in the Euro-EWING99-R1 randomized controlled trial (RCT)
69 comparing cyclophosphamide and ifosfamide in Ewing sarcoma. To further evaluate this
70 interaction, we performed an individual patient data meta-analysis of RCTs assessing
71 cyclophosphamide vs. ifosfamide in any type of cancer. **Methods:** A literature search
72 produced two more eligible RCTs (EICESS92 and IRS-IV). The endpoints were progression-
73 free survival (PFS, main endpoint) and overall survival (OS). The hazard ratios (HR) of the
74 treatment-by-sex interaction and their 95%-confidence interval (95%CI) were assessed using
75 stratified multivariable Cox models. Heterogeneity of the interaction across age categories
76 and trials was explored. We also assessed this interaction for severe acute toxicity using
77 logistic models. **Results:** The meta-analysis comprised 1528 pediatric and young adult
78 sarcoma patients from three RCTs: Euro-EWING99-R1 (n=856), EICESS92 (n=155) and
79 IRS-IV (n=517). There were 224 PFS events in Euro- EWING99-R1 and 200 in the validation
80 set (EICESS92+IRS-IV); and 171 and 154 deaths in each dataset respectively. The estimated
81 treatment-by-sex interaction for PFS in Euro-EWING99-R1 (HR=1.73, 95%CI=1.00-3.00)
82 was not replicated in the validation set (HR=0.97, 95%CI=0.55-1.72), without heterogeneity
83 across trials (p=0.62). In the pooled analysis, the treatment-by-sex interaction was not
84 significant (HR=1.31, 95%CI=0.89-1.95, p=0.17), without heterogeneity across age
85 categories (p=0.88) and trials (p=0.36). Similar results were observed for OS. No significant
86 treatment-by-sex interaction was observed for leucopenia/neutropenia (p=0.45), infection
87 (p=0.64) or renal toxicity (p=0.20). **Conclusion:** Our meta-analysis did not confirm the
88 hypothesis of a treatment-by-sex interaction on efficacy or toxicity outcomes.

INTRODUCTION

The Euro-E.W.I.N.G.99-R1 randomized trial (EE99-R1, NCT00020566)[1] compared the efficacy of cyclophosphamide and ifosfamide combined with vincristine and dactinomycin (VAC vs. VAI) as maintenance treatment in localized standard-risk Ewing sarcoma. We observed that sex marginally modified the treatment effect on event-free survival (EFS, interaction test, $p=0.083$): in males, VAC was associated with poorer EFS than VAI with a hazard ratio (HR) (VAC/VAI) =1.34 (95%CI, 0.96-1.86), whereas VAC was slightly better than VAI in females with a HR=0.83 (95%CI, 0.54-1.28).[2]

Epidemiological studies have reported a higher incidence and mortality among men than women.[3,4] Registry-based survival analyses adjusted for age and disease stage have also shown that survival tends to be worse in males in various cancers.[4,5] Moreover, numerous clinical trials of cancer patients report a worse prognosis in males in most studies.[6–10] There are also sex differences in chemotherapy-related toxicity, especially with alkylating-based chemotherapy, with higher toxicity rates in females, especially hematological toxicity.[2,10–14] Some of these findings regarding efficacy and toxicity can be explained by pharmacokinetic differences in drug metabolism (e.g. different expression of liver metabolizing enzymes according to sex), leading some authors to propose sex-based dose adaptations.[15–18]

However, no interaction between the type of alkylating agent (cyclophosphamide or ifosfamide) and sex on efficacy and acute toxicity outcomes was reported before the EE99-R1 trial. In an attempt to confirm the EE99-R1 observation, we conducted a Meta-Analysis on Interaction between Alkylating agents and Gender (MAIAGE) of randomized controlled trials (RCT) comparing cyclophosphamide versus ifosfamide, to confirm whether or not the effect of these two treatments differs between males and females.

MATERIALS and METHODS

Trial selection

To identify an independent validation set for the EE99-R1 data, we undertook a bibliographic search of clinical trials randomizing cyclophosphamide vs. ifosfamide (possibly in addition to other drugs but these drugs had to be identical in both arms) in both sex, without restriction on patient age and type of cancer. We searched PubMed and The Cochrane Library for articles published between 1980 and 2013 (any language), and the National Institute of Health clinical trials register (<https://clinicaltrials.gov/>). In addition, all participating trialists were asked to review and supplement a provisional list of trials. Trial selection was accomplished by two authors (BF, GLT) and all relevant articles were reviewed by a third (MCLD).

Cyclophosphamide and ifosfamide could have been administered either as a single drug or combined with other drugs, but in the latter case, the only difference between the two arms had to be cyclophosphamide and ifosfamide. Differences in the dosage and infusion duration of cyclophosphamide and ifosfamide were allowed across studies. RCTs comparing only one course of cyclophosphamide or ifosfamide were not eligible. Moreover RCTs for which individual patient data concerning survival and toxicity were not available, were excluded.

Data extraction and trial quality assessment

Individual patient data were collected for each trial: sex, date of birth, allocated treatment, date of randomization, date of first event, type of first event (progression, relapse, secondary malignancy, death), date of last follow-up or death, survival status and cause of death (if applicable). We also collected acute toxicity data for leucopenia/neutropenia, thrombocytopenia, infection, mucositis and diarrhea, renal, liver, cardiac, skin, central and peripheral neurologic toxicities during the randomized period with the grade according to the NCI-CTCAE (Common Terminology Criteria for Adverse Events) grading system. Individual anonymous data were centrally collected (BF, MCLD) and checked using a standard

procedure (See Supplemental Methods S1). We noted missing data, data validity, randomization integrity and follow-up of patients between the two arms.[19]

Statistical analysis

The primary endpoint was progression-free survival (PFS), defined as the time from randomization to progression, recurrence or death from any cause, whichever occurred first.

The secondary endpoint was overall survival (OS), defined as the time from randomization to death from any cause. Patients who had no events were censored at the date of the last follow-up. Analyses were performed on an intention-to-treat basis.

The validation set was analyzed using a multivariable Cox model, stratified by trial and sex, and including treatment (cyclophosphamide vs. ifosfamide) and age as main fixed effects.

Age was divided into 3 categories (< 12, [12-18] and > 18 years) with selected cut-offs close to those defining the different pubertal status for males and females. The hazard ratio (HR) of the treatment effect by sex was measured by an interaction term ("one-stage" model).[20]

Sensitivity analyses were also performed (see Supplemental Methods S2).

The heterogeneity test was assessed by Cochran's Q-statistics and I^2 . [21,22] In addition, we performed an exploratory analysis on all RCTs, i.e. EE99-R1 and the validation set. Stratified PFS curves were used to calculate the absolute difference at 5 years.[23] All statistical analyses performed for the validation set were also repeated on the pooled dataset. To explore heterogeneity of the treatment-by-sex interaction term across all trials and age categories, a 3-order interaction term was included, with the relative 2-order interactions terms.

For each type of acute toxicity, the maximum grade was computed for each patient and dichotomized as follows: hematologic toxicity (<, \geq grade-4), mucositis (<, \geq grade-3), diarrhea (<, \geq grade-3) and infection, renal, liver, cardiac, skin, central and peripheral neurologic toxicities (<, \geq grade-2). The main safety analysis included toxicities which had occurred in at least five males and females in each trial arm to allow interaction analyses:

166 leucopenia/neutropenia, infection, renal toxicity. For each type of toxicity, we estimated the
167 treatment-by-sex interaction term using a logistic regression model stratified by trial and
168 including age category, sex, treatment (main fixed effects) and treatment-by-sex interaction.
169 We assessed the heterogeneity of the interaction across trials using a 3-order interaction term
170 between treatment, sex and trial.

171 All estimates are given with 95% confidence intervals (95%CI) and two-sided p-values. Data
172 collection and statistical analyses were performed using SAS Software 9.3. *Coxme* and *Meta*
173 R packages for R version 3.0.2 (<http://www.R-project.org>) were used respectively to perform
174 Cox regression models with random treatment effects and forest plots. The results are
175 reported according to PRISMA-IPD recommendations.[24]

176

177 **RESULTS**

178 **Trials description**

179 In addition to the EE99-R1 trial[1], we identified three trials (EICESS92[25], IRS-IV[26] and
180 an EORTC randomized phase-II trial in soft tissue sarcomas[27]) among 380 references of
181 published papers and 37 studies registered on ClinicalTrials.gov (Figure-1). The EORTC trial
182 was excluded because the individual patient data (survival and toxicity) were not available.

183 We also excluded three randomized trials conducted exclusively in women (breast cancer[28],
184 ovarian epithelial cancer[29] and endometrial adenocarcinoma[30]). Regarding the IRS-IV
185 trial which compared three parallel groups, we considered the VAI and VAC arms, and
186 excluded the third arm (vincristine-ifosfamide-etoposide arm). Actualization of the literature
187 search in November 2016 did not identify any other trial fulfilling the inclusion criteria.

188 The three RCTs retained were high-quality phase III trials (See Supplemental Methods S1)
189 comparing cyclophosphamide to ifosfamide in multi-drug combinations administered as first-
190 line treatment (Table-1). Sex was considered as a stratification variable in these three trials.

The dose ratio of ifosfamide/cyclophosphamide ranged from 4 to 5. In total, 1528 patients were included, 773 in the cyclophosphamide arm and 755 in the ifosfamide arm. The EE99-R1 trial represented 56% of the total number of patients. These trials were all conducted in sarcomas (Ewing sarcoma, rhabdomyosarcoma and undifferentiated sarcomas). They included children, adolescents and young adults, aged <15 years in 66% of the patients (Table-2).

Survival analysis

With a median follow-up of 6.8 years [Q1-Q3, 4.5-8.9] (5.9 and 8.0 years in EE99-R1 and the validation set containing EICESS92 and IRS-IV, respectively), we observed 424 disease failures (i.e. PFS events: 224 and 200 in EE99-R1 and the validation set, respectively; progression or relapse in 395 patients and death as first event in 29, including 6 treatment-related deaths, 9 from disease progression, 9 other causes and 5 unknown causes). There were 325 deaths overall (171 and 154 in EE99-R1 and the validation set, respectively). The estimated treatment-by-sex interaction on PFS in EE99-R1 (HR=1.73, 95%CI 1.00-3.00, p-value=0.051) was not replicated in the validation set (n=672) using the one-stage model (EICESS92+IRS-IV, HR=0.97, 95%CI 0.55-1.72, p=0.93, Figure-2), with no heterogeneity between both trials (p=0.62). Interaction estimates were very similar in the sensitivity analyses (Table-3). In the same way, the estimated treatment-by-sex interaction in EE99-R1 for OS (HR=1.85, 95%CI 0.98-3.48, p=0.056) was not replicated in the validation set (HR=1.00, 95%CI 0.52-1.92, p=0.99, Supplemental Figure-1).

When the three RCTs were pooled, the estimated 5-year absolute PFS benefit associated with ifosfamide compared to cyclophosphamide was greater among males +6.0% (73.7% vs 67.9%), than females (+0.2%, 75.2% vs 75.0%, Figure-3). However, the overall estimate of treatment-by-sex interaction was not statistically significant (HR=1.31, 95%CI 0.89-1.95, p=0.17). Although a significant treatment-by-sex interaction was observed in EE99-R1

($p=0.051$), this interaction was not statistically different to interaction terms estimated in EICESS92 and IRS-IV trials ($p=0.36$, Figure-2). This interaction estimate did not vary across age categories ($p=0.88$, Supplemental Figure S2). The sensitivity analyses yielded similar results (last column, Table-3). For OS (Supplemental Figure S3), the pooled estimate of the treatment-by-sex interaction was not statistically significant ($HR=1.37$, 95%CI 0.87-2.15, $p=0.17$). We observed neither heterogeneity across trials ($p=0.35$, Figure-4) nor across age categories ($p=0.64$, Supplemental Figure S4). Stable results were observed in the sensitivity analyses (Table-3).

Toxicity analysis

The frequencies of severe acute toxicities by sex and treatment arm are shown in Supplemental Table S1. At least one episode of severe acute neutropenia, infection and renal toxicity had occurred in 69.8%, 52.8% and 7.8% of patients, respectively. As illustrated in Supplemental Figures S5-7, no significant interaction was identified between sex and alkylating agent for leucopenia/neutropenia ($OR=0.82$, 95%CI 0.49-1.36, $p=0.43$), infection ($OR=1.11$, 95%CI 0.71-1.71, $p=0.65$), or renal toxicity ($OR=1.71$, 95%CI 0.76-3.85, $p=0.19$). These estimates did not significantly vary across trials (heterogeneity tests for leucopenia/neutropenia: $p=0.81$, infection: $p=0.12$, and renal toxicity: $p=0.19$). The main effects were reported because no interaction was found between treatment and sex. Compared to ifosfamide, patients receiving cyclophosphamide experienced more severe leucopenia/neutropenia ($OR_{cyclo\ vs\ ifo}=1.47$, 95%CI 1.14-1.88, $p=0.003$) and infections ($OR_{cyclo\ vs\ ifo}=1.55$, 95%CI 1.25-1.93, $p<0.0001$), but less renal toxicity ($OR_{cyclo\ vs\ ifo}=0.71$, 95%CI 0.48-1.06, $p=0.098$). Regardless of treatment arm, females developed significantly more severe leucopenia/neutropenia ($OR_{female\ vs\ male}=1.39$, 95%CI 1.08-1.79, $p=0.013$) and

infections ($OR_{\text{female vs male}}=1.25$, 95%CI 1.01-1.56, $p=0.041$) than males, but not significantly more severe renal toxicity ($OR_{\text{female vs male}}=1.22$, 95%CI 0.83-1.82, $p=0.32$).

DISCUSSION

Using an independent validation set of two RCTs (EICESS92 and IRS-IV), we did not replicate the treatment-by-sex interactions observed in the EE99-R1 trial on PFS and OS. No significant interactions were observed when the three trials were pooled, with no significant heterogeneity across age and trials. Similarly, we did not identify any treatment-by-sex interaction on leucopenia/neutropenia, infection and renal toxicity. Cyclophosphamide was significantly more hemato-toxic (leucopenia/neutropenia and infections) than ifosfamide. We also observed more hemato-toxicity in women than in males regardless of treatment arm.

This individual patient data meta-analysis is the first to assess a potential interaction between the type of alkylating agent and sex. Based on high-quality RCTs comparing cyclophosphamide to ifosfamide in both sex, with a total number of patients exceeding 1, 500 and long follow-up, it provides an unbiased estimate of the treatment-by-sex interaction. Finally, even though the search was not restricted to age or to a specific type of cancer, these three trials included mainly pediatric and young adult patients, with Ewing sarcoma or rhabdomyosarcoma under first-line treatment. This probably reduces sources of heterogeneity across trials (e.g. pharmacodynamic differences, co-morbidity, etc.).

The EORTC trial [27] which randomized cyclophosphamide and ifosfamide as a single drug in advanced or metastatic soft-tissue sarcomas ($n=135$ patients) was not included in the MAIAGE study due to the lack of availability of individual survival or toxicity data after contacting the principal investigator. This study reported lower response rates in the cyclophosphamide arm than in the ifosfamide arm, especially in males (observed response rate of 0% and 11% in males treated with cyclophosphamide and ifosfamide, respectively,

265 and of 17% and 23% in females). Based on these data, we did not observe any significant
266 heterogeneity of the treatment effect between sex (interaction test: $p=0.12$). In the three other
267 randomized trials excluded (because they were based on women only, see Appendix) [28-30],
268 a better prognosis was reported in two, in subgroups of women treated with ifosfamide
269 [29,30] whereas the difference was not significant in the third trial.[28]

270 Our study had some limitations. First, none of the trials analyzed were initially designed to
271 study a treatment-by-sex interaction. Due to the observed number of events in each trial and
272 when pooled, the analyses could be underpowered to test the interaction with a standard
273 statistical level ($p<0.05$), let alone to detect heterogeneity of the treatment-by-sex interaction
274 across trials (e.g. infection analysis with marginal heterogeneity across trials, $p=0.12$).
275 Although we did not validate a treatment-by-sex interaction on efficacy outcomes, our results
276 do not conclusively rule out the existence of an interaction.

277 Second, in addition to the index trial, we identified only two other RCTs, which together
278 contributed less than 50% of the total number of patients. We did not identify any other study
279 comparing cyclophosphamide and ifosfamide, hence there is a paucity of independent trials.
280 Finally, differences in population characteristics and in drug combinations in the backbone
281 chemotherapy could impact the consistency of the estimates of treatment-by-sex interaction.
282 Indeed, (i) rhabdomyosarcoma patients in IRS-IV were younger than Ewing sarcoma patients
283 from the other two trials, and (ii) all IRS-IV patients received four additional courses with
284 cyclophosphamide after the first eight courses allocated by randomization; in contrast, all
285 patients also received ifosfamide as induction chemotherapy before randomization in both
286 Ewing sarcoma trials.

287 Our findings concerning acute toxicity are consistent with previous reports in sarcoma and
288 lymphoma patients treated with alkylating agents.[10–14] Differences in cytochrome P450-
289 mediated drug metabolism between sex could explain these results. Cyclophosphamide and

ifosfamide are oxazaphosphorine alkylating prodrugs that are metabolized via different P450-catalyzed pathways: (i) 4-hydroxylation produces active alkylating agents and urotoxic acrolein via CYP2B6 for cyclophosphamide and CYP3A4 and CYP3A5 for ifosfamide, and (ii) N-dechloroethylation generates inactive metabolites and nephro- and neuro-toxic chloroacetaldehyde via CYP3A4 for cyclophosphamide and, to a much greater extent, CYP3A4 and CYP2B6 for ifosfamide.[31–33] Greater activity of CYP3A4 and CYP2B6 has been reported in females resulting in higher concentrations of toxic chloroacetaldehyde after ifosfamide infusion and consequently in a possible higher risk of severe neurotoxicity in females.[34–36] However, no cytochrome P450-related difference in hematologic toxicity between sex has previously been reported.

In conclusion, our meta-analysis did not show that the treatment effect of cyclophosphamide versus ifosfamide is influenced by sex, for either efficacy or toxicity. Therefore, recommending the choice of alkylating agent should not need be based on sex in children and young adults treated for sarcoma. Additional studies would be useful for long-term follow-up including fertility outcomes.

306 **DISCLOSURE**

307 **Conflict of Interest:** The authors have no conflict of interest to disclose.

308 **Funding Source:** This research was supported by

- 309 - The Gustave-Roussy Institute,
- 310 - The Fondation pour la Recherche Médicale;
- 311 - European Community’s Seventh Framework Programme under grant agreements No.
- 312 261474 (project ENCCA) and No. 602856-2 (project EEC);
- 313 - Fédération Enfants et Santé, Société Française de Lutte Contre les Cancers et les
- 314 Leucémies de l’Enfant et de l’Adolescent,
- 315 - Unicancer and the Ligue Nationale Contre le Cancer;
- 316 - Cancer Research UK (Grant No. CRUK/02/014) ;
- 317 - Deutsche Krebshilfe (Grants No. 50-2551-Jü3, 50-2551-Jü4, DKH-108128, 70-2551-
- 318 Jue3 and 108128), and Bundesministerium für Bildung und Forschung (TranSaRNet
- 319 and Grants No. BMBF 01GM0869 and BMBF/Era-Net 01KT1310), Deutsches
- 320 Zentrum für Luft- und Raumfahrt e.V. 01GM0869,
- 321 - The National Cancer Institute, Bethesda, MD (grants U10CA180886, U10CA180899,
- 322 U10CA098543, and U10CA098413).

323 **Financial Disclosure:** The authors have no financial relationships relevant to this article to
324 disclose.

325 **Acknowledgments:** Special thanks for assistance to Joachim Boos for helpful discussions and
326 Lorna Saint Ange for editing.
327

REFERENCES

- [1] Le Deley M-C, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. *J Clin Oncol* 2014;32:2440–8.
- [2] van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, et al. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial. *Eur J Cancer* 2015;51:2453-64.
- [3] Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, et al. Sex disparities in cancer incidence by period and age. *Cancer Epidemiol Biomarkers Prev* 2009;18:1174–82.
- [4] Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. *Cancer Epidemiol Biomarkers Prev* 2011;20:1629–37.
- [5] Khamly KK, Thursfield VJ, Fay M, Desai J, Toner GC, Choong PFM, et al. Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. *Int J Cancer* 2009;125:426–31.
- [6] Molife R, Lorigan P, MacNeil S. Gender and survival in malignant tumours. *Cancer Treat Rev* 2001;27:201–9.
- [7] Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. *J Clin Oncol* 1997;15:2040–9.

- 352 [8] Glynn-Jones R, Sebag-Montefiore D, Adams R, Gollins S, Harrison M, Meadows HM,
353 et al. Prognostic factors for recurrence and survival in anal cancer: generating
354 hypotheses from the mature outcomes of the first United Kingdom Coordinating
355 Committee on Cancer Research Anal Cancer Trial (ACT I). *Cancer* 2013;119:748–55.
- 356 [9] Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, et al. Survival
357 differences by sex for patients with advanced non-small cell lung cancer on Eastern
358 Cooperative Oncology Group trial 1594. *J Thorac Oncol* 2006;1:441–6.
- 359 [10] Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J, Bielack S, et al. Benefits and
360 adverse events in younger versus older patients receiving neoadjuvant chemotherapy for
361 osteosarcoma: findings from a meta-analysis. *J Clin Oncol* 2013;31:2303–12.
- 362 [11] Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M, et al. Sex- and age-
363 related chemotherapy toxicity in patients with non-metastatic osteosarcoma. *J*
364 *Chemother* 2009;21:205–10.
- 365 [12] Paioli A, Luksch R, Fagioli F, Tamburini A, Cesari M, Palmerini E, et al.
366 Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence
367 of sex and age. *J Chemother* 2014;26:49–56.
- 368 [13] Wrobel G, Mauguén A, Rosolen A, Reiter A, Williams D, Horibe K, et al. Safety
369 assessment of intensive induction therapy in childhood anaplastic large cell lymphoma:
370 report of the ALCL99 randomised trial. *Pediatr Blood Cancer* 2011;56:1071–7.
- 371 [14] Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, et al. Safety
372 assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and
373 etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical
374 trial. *Pediatr Blood Cancer* 2006;47:22–9.

- 375 [15] Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics:
376 interaction with biological differences between men and women. *Br J Pharmacol*
377 2014;171:580–94.
- 378 [16] Anderson GD. Sex and racial differences in pharmacological response: where is the
379 evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. *J Womens*
380 *Health* 2005;14:19–29.
- 381 [17] Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug
382 metabolizing enzymes. *Mol Pharmacol* 2009;76:215–28.
- 383 [18] Schmetzer O, Flörcken A. Sex differences in the drug therapy for oncologic diseases.
384 *Handb Exp Pharmacol* 2012:411–42.
- 385 [19] Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using
386 updated individual patient data. Cochrane Working Group. *Stat Med* 1995;14:2057–79.
- 387 [20] Fisher DJ, Copas AJ, Tierney JF, Parmar MKB. A critical review of methods for the
388 assessment of patient-level interactions in individual participant data meta-analysis of
389 randomized trials, and guidance for practitioners. *J Clin Epidemiol* 2011;64:949–67.
- 390 [21] Cochran WG. The Combination of Estimates from Different Experiments. *Biometrics*
391 1954;10:101.
- 392 [22] Higgins JPT. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
- 393 [23] Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast
394 cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving
395 31,000 recurrences and 24,000 deaths among 75,000 women. *Lancet* 1992;339:71–85.
- 396 [24] Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred
397 Reporting Items for Systematic Review and Meta-Analyses of individual participant
398 data: the PRISMA-IPD Statement. *JAMA* 2015;313:1657–65.

- 399 [25] Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, et al. Results of the
400 EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--
401 cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of
402 benefit of etoposide added to standard treatment in high-risk patients. *J Clin Oncol*
403 2008;26:4385-93.
- 404 [26] Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup
405 rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. *J Clin*
406 *Oncol* 2001;19:3091-102.
- 407 [27] Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, et al.
408 Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult
409 soft tissue sarcomas. *Eur J Cancer Clin Oncol* 1987;23:311-21.
- 410 [28] Buzdar AU, Legha SS, Tashima CK, Yap HY, Hortobagyi GN, Hersh EM, et al.
411 Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast
412 cancer. *Cancer Treat Rep* 1979;63:115-20.
- 413 [29] Nishida T, Sugiyama T, Yakushiji M. Cisplatin, epirubicin, and ifosfamide versus
414 cisplatin, epirubicin, and cyclophosphamide in clear cell carcinoma of the ovary.
415 *Gynecol Oncol* 1997;67:230.
- 416 [30] Pawinski A, Tumolo S, Hoesel G, Cervantes A, van Oosterom AT, Boes GH, et al.
417 Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial
418 carcinoma: a randomized phase II study of the EORTC Gynecological Cancer
419 Cooperative Group. *Eur J Obstet Gynecol Reprod Biol* 1999;86:179-83.
- 420 [31] Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, et al.
421 Identification of the major human hepatic cytochrome P450 involved in activation and
422 N-dechloroethylation of ifosfamide. *Biochem Pharmacol* 1994;47:1157-63.

- 423 [32] Roy P, Tretyakov O, Wright J, Waxman DJ. Stereoselective metabolism of ifosfamide
424 by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug
425 Metab Dispos Biol Fate Chem 1999;27:1309–18.
- 426 [33] Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6
427 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem
428 Pharmacol 2000;59:961–72.
- 429 [34] Schmidt R, Baumann F, Hanschmann H, Geissler F, Preiss R. Gender difference in
430 ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet
431 2001;26:193–200.
- 432 [35] Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, et al. Sex is a
433 major determinant of CYP3A4 expression in human liver. Hepatology 2003;38:978–88.
- 434 [36] Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, et al. Hepatic CYP2B6
435 expression: gender and ethnic differences and relationship to CYP2B6 genotype and
436 CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther
437 2003;307:906–22.
- 438 [37] Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after
439 myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis
440 1985;27:335–71.

441

442

FIGURE LEGENDS

Figure 1: Flow chart of trial selection process.

C=Cyclophosphamide, I=Ifosfamide, STS=Soft tissue sarcoma.

*The search strategy used the following search terms: "Ifosfamide"[Mesh] AND "Cyclophosphamide"[Mesh] AND ("Randomized Controlled Trial" [Publication Type] OR "Controlled Clinical Trial" [Publication Type]) in PubMed, "Ifosfamide" AND "Cyclophosphamide" in the Cochrane Library, and "Ifosfamide" AND "Cyclophosphamide" AND "Randomized" in the NIH clinical trials register (<http://www.clinicaltrials.gov>).

Notes: Euro-EWING99-R1 trial was not yet published when we conducted the systematic review, that is why it does not appear in the initial systematic review box. Actualization of the literature search in November 2016 did not identify any other trial fulfilling the inclusion criteria.

Figure 2: Forest plot of the hazard ratios (HR) of progression-free survival in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex using fixed effects model.

The hazard ratios (HRs) given on the right side represent the HR of the treatment-by-sex interaction (HRCyclo/Ifo in males/ HRCyclo/Ifo in females) estimated independently for each trial, in the validation set and in the pooled dataset, by the one-stage model, stratified by trial and sex, and including treatment (cyclophosphamide vs. ifosfamide) and age (< 12, 12-18, and >18 years) as the main fixed effects. The heterogeneity of the interaction across trials was assessed using a 3-order interaction term. The center of each square represents the HR for individual trials and for the validation set (EICESS92 + IRS-IV) and the corresponding

horizontal line its 95% confidence interval (CI). The area of squares is proportional to the amount of information obtained from the trial. The center of the black diamond represents the overall HR and the extremities of the diamond represent its 95% CI, both estimated from the pooled dataset.

Figure 3: Stratified progression-free survival (PFS) curves according to sex and alkylating agent (cyclophosphamide or ifosfamide) when the 3 RCTs were pooled (n=1528).

The 5-year absolute PFS benefit associated with ifosfamide (Ifo) compared to cyclophosphamide (Cyclo) was estimated at 6% in males (73.7% vs. 67.9%), whereas females receiving ifosfamide or cyclophosphamide had similar PFS (75.2% vs. 75.0%, difference=0.2%).

484 **SUPPLEMENTAL MATERIAL LEGENDS**

485

486 **1. Supplementary methods**

487 Supplemental Methods S1: Procedure of data checking

488 Supplemental Methods S2: Statistical methods for sensitivity analyses

489

490 **2. Supplementary results of survival analyses**

491 Supplemental Figure S1: Forest plot of the hazard ratios (HR) of death (overall
492 survival) in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex
493 using fixed effects models.

494 Supplemental Figure S2: Forest plot of the hazard ratios (HR) of progression-free
495 survival in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex
496 for each age category (<12 years, 12-18 years, >18 years) using fixed effects models
497 when the 3 trials were pooled.

498 Supplemental Figure S3: Stratified overall survival (OS) curves according to sex and
499 alkylating agent (cyclophosphamide or ifosfamide) when the 3 trials were pooled.

500 Supplemental Figure S4: Forest plot of the hazard ratios (HR) of overall survival in the
501 cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex for each age
502 category (<12 years, 12-18 years, >18 years) using fixed effects models when the 3
503 trials were pooled.

504

505 **3. Detailed results of toxicity analyses**

506 Supplemental Table S1: Number of patients in each trial who experienced at least one
507 episode of severe acute toxicity by sex and by treatment arm.

508 Supplemental Figure S5: Forest plot of the odd ratios (OR) of leucopenia/neutropenia
509 in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex when the
510 3 trials were pooled.

511 Supplemental Figure S6: Forest plot of the odd ratios (OR) of infection in the
512 cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex when the 3
513 trials were pooled.

514 Supplemental Figure S7: Forest plot of the odd ratios (OR) of renal toxicity in the
515 cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex when the 3
516 trials were pooled.

517

518 **4. Description of the randomized controlled trials comparing alkylating agents, not**
519 **included in the meta-analysis**

520 Supplemental Table S2: Information extracted from the 3 randomized trials conducted
521 in women and not included in the meta-analysis




Figure 1: Flow chart of trial selection process.

C=Cyclophosphamide, I=Ifosfamide, STS=Soft tissue sarcoma.

*The search strategy used the following search terms: "Ifosfamide"[Mesh] AND "Cyclophosphamide"[Mesh] AND ("Randomized Controlled Trial" [Publication Type] OR "Controlled Clinical Trial" [Publication Type]) in PubMed, "Ifosfamide" AND "Cyclophosphamide" in the Cochrane Library, and "Ifosfamide" AND "Cyclophosphamide" AND "Randomized" in the NIH clinical trials register (<http://www.clinicaltrials.gov>).

Notes: Euro-EWING99-R1 trial was not yet published when we conducted the systematic review, that is why it does not appear in the initial systematic review box. Actualization of the literature search in November 2016 did not identify any other trial fulfilling the inclusion criteria.




Figure 2: Forest plot of the hazard ratios (HR) of progression-free survival in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by gender using fixed effects model.

The hazard ratios (HRs) given on the right side represent the HR of the treatment-by-gender interaction (HRCyclo/Ifo in males/ HRCyclo/Ifo in females) estimated independently for each trial, in the validation set and in the pooled dataset, by the one-stage model, stratified by trial and gender, and including treatment (cyclophosphamide vs. ifosfamide) and age (< 12, 12-18, and >18 years) as the main fixed effects. The heterogeneity of the interaction across trials was assessed using a 3-order interaction term. The center of each square represents the HR for individual trials and for the validation set (EICESS92 + IRS-IV) and the corresponding horizontal line its 95% confidence interval (CI). The area of squares is proportional to the amount of information obtained from the trial. The center of the black diamond represents the overall HR and the extremities of the diamond represent its 95% CI, both estimated from the pooled dataset.

190x142mm (300 x 300 DPI)




Figure 3: Stratified progression-free survival (PFS) curves according to gender and alkylating agent (cyclophosphamide or ifosfamide) when the 3 RCTs were pooled (n=1528).

The 5-year absolute PFS benefit associated with ifosfamide (Ifo) compared to cyclophosphamide (Cyclo) was estimated at 6% in males (73.7% vs. 67.9%), whereas females receiving ifosfamide or cyclophosphamide had similar PFS (75.2% vs. 75.0%, difference=0.2%).

190x142mm (300 x 300 DPI)

TABLE 1 Characteristics of selected randomized clinical trials with regimens comparing cyclophosphamide versus ifosfamide.

Trial ^(ref)	Accrual period	Type of trial and design	N	Median follow-up [Q1-Q3]	Inclusion criteria			Eligibility criteria for randomization	Randomized regimens		Primary endpoint	Results of ITT [†] analysis
					Pathology [‡]	Primary tumor site	Age (years)		Ifo (dose/3w)	Cyclo (dose/3w)		
EE99-R1 ⁽¹⁾	2000-2010	Multicentric Phase III Non-inferiority	856	5.9 [3.8; 8.0]	EWS	Bone or soft tissue	< 50	Localized tumors With a good response to preoperative CT*	7 VAI (3 g/m ² x2)	7 VAC (1.5 g/m ² x1)	3y-EFS	78% (VAI) 75% (VAC)
ECESS92 ⁽²⁵⁾	1992-1999	Multicentric Phase III Non-inferiority	155	8.3 [6.9; 10.6]	ESFT	Bone	< 35	Localized tumors of less than 100mL	10 VAIA (2 g/m ² x3)	10 VACA (1.2 g/m ² x1)	3y-EFS	74% (VAIA) 73% (VACA)
IRS-IV ⁽²⁶⁾	1991-1997	Multicentric Phase III Superiority	517	8.0 [5.5; 9.9]	RMS, undifferentiated sarcoma	Soft tissue	< 21	Localized tumors**	8 VAI [◊] (1.8 g/m ² x5)	8 VAC (2.2 g/m ² x1)	3y-EFS	77% (VAI) 73% (VAC)

N: number of randomized patients, Cyclo: cyclophosphamide, Ifo: Ifosfamide, CT : chemotherapy, VAI : vincristine, dactinomycin, ifosfamide, VAC: vincristine, dactinomycin, cyclophosphamide, VAIA: vincristine, dactinomycin, ifosfamide, adriamycin, VACA: vincristine, dactinomycin, cyclophosphamide, adriamycin, EFS: event-free survival, Q1: first quartile, Q3: third quartile.

‡: EWS: Ewing sarcoma, ESFT: Ewing sarcoma family of tumors, RMS: rhabdomyosarcoma.

†: Intention to Treat. , w: week, y: year

* patients with either a good histologic response to preoperative treatment (<10% cells), or a small tumor (< 200 mL) resected at diagnosis or with radiotherapy alone as local treatment.

** after exclusion of patients with completely resected paratesticular tumors, completely resected or microscopic residual disease of orbit or eyelid tumors, pre-existing renal abnormalities.

TABLE 2 Characteristics of randomized patients in each trial included in the meta-analysis.

	EE99-R1		EICESS92		IRS-IV		Pooled dataset	
	VAI (n=425)	VAC (n=431)	VAIA (n=76)	VACA (n=79)	VAI (n=254)	VAC (n=263)	Ifo arm (n=755)	Cyclo arm (n=773)
Sex								
- male	251	258	46	49	141	152	438	459
- female	174	173	30	30	113	111	317	314
Age (years)								
Median	14.0	14.6	15.4	13.8	6.0	5.0	11.8	12.0
[0 ; 10[120	99	17	18	172	190	309	307
[10 ; 15[127	127	19	31	54	39	200	197
[15 ; 20[88	107	23	17	28	32	139	156
≥20	90	98	17	13		2	107	113
Pathology								
- ESFT	415	416	73	77			488	493
- RMS					234	248	234	248
- Other bone sarcoma	1	1	1				2	1
- Other STS	10	14	2	2	20	15	32	31
Tumor stage								
- Localized disease	425	430	72	78	244	253	741	761
- Metastatic disease		1	3	1			3	2
- NA			1		10	10	11	10
Number of events	106	118	28	28	62	82	196	228
- Progression/relapse	102	115	27	27	55	69	184	211
- Death as first event	4	3	1	1	7	13	12	17
Number of deaths	83	88	18	21	51	64	152	173

VAI: vincristine, dactinomycin, ifosfamide, VAC: vincristine, dactinomycin, cyclophosphamide, VAIA: vincristine, dactinomycin, ifosfamide, adriamycin, VACA: vincristine, dactinomycin, cyclophosphamide, adriamycin, Ifo: ifosfamide, Cyclo: cyclophosphamide, CT: chemotherapy, ESFT: Ewing sarcoma family of tumors, RMS: rhabdomyosarcoma, STS: soft tissue sarcoma, NA: not applicable.

TABLE 3 Estimate of the hazard ratio of the treatment-by-gender interaction term for progression-free survival and overall survival for EE99-R1 (training set), EICESS92 + IRS-IV (validation set) and the pooled dataset in the main and sensitivity analyses.

	Training set EE99-R1 (n=856) HR (95%CI)	Validation set EICESS92 + IRS-IV (n=672) HR (95%CI)	Pooled analysis EE99-R1 + EICESS92 + IRS-IV (n=1528) HR (95%CI)
Progression-free survival			
- Main analysis: OSM, fixed effects, age category	1.73 (1.00-3.00), p=0.051	0.97 (0.55-1.72), p=0.93	1.31 (0.89;1.95), p=0.17
- Sensitivity analyses			
* OSM, random effects, age category	1.73 (1.00-3.00), p=0.051	0.98 (0.55-1.73), p=0.93	1.32 (0.89;1.95), p=0.17
* OSM, fixed effects, age continuous	1.71 (0.98-2.96), p=0.057	0.96 (0.55-1.71), p=0.90	1.31 (0.89-1.95), p=0.17
* PWT, fixed effects, age category		0.97 (0.55-1.73), p=0.92	1.32 (0.88;1.96), p=0.18
Overall survival			
- Main analysis: OSM, fixed effects, age category	1.85 (0.98-3.48), p=0.056	1.00 (0.52-1.92), p=0.99	1.37 (0.87;2.15), p=0.17
- Sensitivity analyses			
* OSM, random effects, age category	1.85 (0.98-3.48), p=0.056	1.00 (0.52-1.93), p=1.00	1.37 (0.87;2.16), p=0.17
* OSM, fixed effects, age continuous	1.80 (0.96-3.38), p=0.068	0.99 (0.51-1.91), p=0.98	1.37 (0.87;2.16), p=0.17
* PWT, fixed effects, age category		0.99 (0.51-1.91), p=0.98	1.37 (0.87;2.16), p=0.17

HR: hazard ratio of the treatment-by-gender interaction term (HR Cyclo vs. Ifo in males / HR Cyclo vs. Ifo in Females)

95%CI: 95% Confidence Interval

OSM: one-stage model; PWT: pooling of within-trial covariate interactions model; age category: <12 years, [12-18] years and >18 years

Supplementary material

1. Supplementary methods

Supplemental Methods S1: Procedure of data checking

Supplemental Methods S2: Statistical methods for sensitivity analyses

2. Supplementary results of survival analyses

3. Detailed results of toxicity analyses

4. Description of the randomized controlled trials comparing alkylating agents, not included in the meta-analysis

1. Supplementary methods

Supplemental Methods S1: Procedure of data checking

We have checked the data according to a standardized procedure¹. Missing values and discrepancies were discussed with the trialists. Randomization validity was assessed by checking the patterns of treatment allocation and the balance in baseline characteristics between treatment groups. Definition of population set was evaluated for each trial to perform the meta-analysis according to the intention-to-treat principle. Patients follow-up was also compared between treatment groups. Each trial was then reanalyzed and the analyses were sent to the trialists for validation.

A. Randomization validity

Curves representing cumulative accrual were plotted and compared between treatment arms: no bias was observed. Among the selected trials, an imbalance between the baseline characteristics of the treatment arms was not detected (See Table 2).

B. Definition of the population sets

Respect of the intention-to-treat principle was requested for randomized trials even if some patients were excluded in the initial analyses of the trial. Overall, 65 randomized patients had been excluded in the initial trial publications, all in the IRS-IV trial. These 65 patients were included in the meta-analysis.

¹ Stewart LA, Clarke MJ on behalf of the Cochrane Working Group on meta-analyses using individual patient data. Practical methodology of meta-analyses (overviews) using updated individual patients data. Stat Med 1995;14:2057-2079.

C. Follow-up

For each treatment arm, reverse Kaplan-Meier curves were plotted: no bias was observed. Median follow-up was 6.8 years [Q1:4.5; Q3:8.9] in the pooled dataset and there was no difference between treatment arms within each trial (EE99-R1: 5.9 and 6.0 for VAC and VAI, respectively. EICESS92: 8.2 and 8.3 for VAIA and VACA, respectively. IRS-IV: 7.7 and 8.1 for VAI and VAC, respectively).


Supplemental Methods S2: Statistical methods for sensitivity analyses

Several pre-specified sensitivity analyses were performed:

- (i) The addition of a study-specific random component for the treatment effect in the one-stage method (OSM);
- (ii) The impact of a misspecification of age was evaluated by including age as a continuous covariate in the OSM;
- (iii) We used the “two-stage” approach to assess the overall treatment-by-sex interaction (“pooling within-trial covariate interactions” method, PWT).[20] We estimated interaction coefficients independently within each trial using multivariable Cox regression models, and then pooled them using the inverse-variance technique with fixed effects.[37]

1. Supplementary results of survival analyses


Supplemental Figure S1: Forest plot of the hazard ratios (HR) of death (overall survival) in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifos) arm by sex using fixed effects models.



Test for heterogeneity for the interaction term: $p = 0.35$


Overall treatment-by-gender interaction : $p = 0.17$

Supplemental Figure S2: Forest plot of the hazard ratios (HR) of progression-free survival in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex for each age category (<12 years, 12-18 years, >18 years) using fixed effects models when the 3 trials were pooled.



Test for heterogeneity for the interaction term: p= 0.88

Supplemental Figure S3: Stratified overall survival (OS) curves according to sex and alkylating agent (cyclophosphamide or ifosfamide) when the 3 trials were pooled.




No. of deaths / person-years by period

Females-Ifo	11/303	14/281	14/248	8/211	7/184	3/150	0/123	2/97
Females-Cyclo	14/304	15/283	15/257	6/220	4/196	4/172	0/145	0/115
Males-Ifo	14/427	27/398	23/357	10/313	8/270	6/232	3/186	0/139
Males-Cyclo	18/439	28/402	18/358	18/314	10/273	8/230	4/184	5/137

The 5-year absolute OS benefit associated with ifosfamide (Ifo) compared to cyclophosphamide (Cyclo) was estimated at +2.2% in males (79.7% vs. 77.5%) and -1.1% in females (80.4% vs. 81.5%).

Supplemental Figure S4: Forest plot of the hazard ratios (HR) of overall survival in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex for each age category (<12 years, 12-18 years, >18 years) using fixed effects models when the 3 trials were pooled.



Test for heterogeneity for the interaction term: p= 0.64

2. Detailed results of toxicity analyses

Supplemental Table S1: Number of patients in each trial who experienced at least one episode of severe acute toxicity by sex and by treatment arm.


Acute toxicity	Sex	Treatment	Number of patients with acute toxicity / number of patients with available information (%)					
			EE99-R1 (n=814)		EICES92 (n=129)		IRS-IV (n=486)	
Leucopenia/neutropenia	Female	VAC	131	/ 152 (86.2)	14	/ 25 (56.0)	75	/ 106 (70.8)
		VAI	124	/ 155 (80.0)	12	/ 25 (48.0)	67	/ 105 (63.8)
	Male	VAC	181	/ 234 (77.4)	16	/ 40 (40.0)	90	/ 142 (63.4)
		VAI	161	/ 225 (71.6)	10	/ 37 (27.0)	81	/ 133 (60.9)
Infection	Female	VAC	90	/ 161 (55.9)	13	/ 25 (52.0)	73	/ 106 (68.9)
		VAI	89	/ 161 (55.3)	9	/ 25 (36.0)	56	/ 105 (53.3)
	Male	VAC	127	/ 246 (51.6)	20	/ 40 (50.0)	87	/ 142 (61.3)
		VAI	88	/ 240 (36.7)	15	/ 37 (40.5)	75	/ 133 (56.4)
Renal toxicity*	Female	VAC	8	/ 160 (5.0)	5	/ 24 (20.8)	5	/ 106 (4.7)
		VAI	22	/ 160 (13.8)	6	/ 25 (24.0)	5	/ 105 (4.8)
	Male	VAC	13	/ 246 (5.3)	9	/ 40 (22.5)	7	/ 142 (4.9)
		VAI	12	/ 239 (5.0)	5	/ 38 (13.2)	13	/ 133 (9.8)
Thrombocytopenia	Female	VAC	79	/ 161 (49.1)	4	/ 25 (16.0)	57	/ 106 (53.8)
		VAI	72	/ 161 (44.7)	0	/ 25 (0.0)	38	/ 105 (36.2)
	Male	VAC	102	/ 245 (41.6)	4	/ 40 (10.0)	70	/ 142 (49.3)
		VAI	64	/ 241 (26.6)	1	/ 37 (2.7)	36	/ 133 (27.1)
Mucositis	Female	VAC	6	/ 160 (3.8)	3	/ 25 (12.0)	59	/ 106 (55.7)
		VAI	6	/ 160 (3.8)	0	/ 24 (0.0)	40	/ 105 (38.1)
	Male	VAC	5	/ 246 (2.0)	3	/ 39 (7.7)	50	/ 142 (35.2)
		VAI	5	/ 240 (2.1)	2	/ 37 (5.4)	55	/ 133 (41.4)
Diarrhea	Female	VAC	1	/ 160 (0.6)	1	/ 12 (8.3)	18	/ 106 (17.0)
		VAI	5	/ 160 (3.1)	0	/ 14 (0.0)	9	/ 105 (8.6)
	Male	VAC	4	/ 246 (1.6)	1	/ 23 (4.3)	18	/ 142 (12.7)
		VAI	1	/ 240 (0.4)	0	/ 26 (0.0)	12	/ 133 (9.0)
Liver toxicity	Female	VAC	7	/ 160 (4.4)	1	/ 25 (4.0)	15	/ 106 (14.2)
		VAI	11	/ 159 (6.9)	2	/ 24 (8.3)	9	/ 105 (8.6)
	Male	VAC	15	/ 245 (6.1)	3	/ 38 (7.9)	23	/ 142 (16.2)
		VAI	9	/ 239 (3.8)	0	/ 37 (0.0)	8	/ 133 (6.0)
Central neurologic toxicity	Female	VAC	1	/ 160 (0.6)	2	/ 24 (8.3)	5	/ 106 (4.7)
		VAI	4	/ 160 (2.5)	0	/ 24 (0.0)	7	/ 105 (6.7)
	Male	VAC	2	/ 244 (0.8)	0	/ 39 (0.0)	7	/ 142 (4.9)
		VAI	3	/ 240 (1.3)	0	/ 36 (0.0)	6	/ 133 (4.5)
Peripheral neurologic toxicity	Female	VAC	11	/ 159 (6.9)	3	/ 25 (12.0)	26	/ 106 (24.5)
		VAI	15	/ 159 (9.4)	1	/ 24 (4.2)	25	/ 105 (23.8)
	Male	VAC	17	/ 245 (6.9)	3	/ 39 (7.7)	35	/ 142 (24.6)
		VAI	8	/ 240 (3.3)	2	/ 37 (5.4)	34	/ 133 (25.6)
Cardiac toxicity	Female	VAC	3	/ 133 (2.3)	5	/ 23 (21.7)	2	/ 106 (1.9)
		VAI	9	/ 143 (6.3)	4	/ 22 (18.2)	2	/ 105 (1.9)
	Male	VAC	6	/ 210 (2.9)	8	/ 36 (22.2)	3	/ 142 (2.1)
		VAI	6	/ 208 (2.9)	8	/ 33 (24.2)	1	/ 133 (0.8)

VAI: vincristine, dactinomycin, ifosfamide, VAC: vincristine, dactinomycin, cyclophosphamide

Adverse events were evaluated using the NCI CTCAE-v2 scale in the EE99-R1 and EICESS92 trials, and NCI CTCAE-v1 scale in the IRS-IV trial.

*Severe renal toxicity (grade 2 or more): at least one episode of increased plasmatic creatinine > 1.5 baseline, or a glomerular filtration rate decrease <60ml/min/1.73m² or a tubular phosphate reabsorption decrease <80%.

Supplemental Figure S5: Forest plot of the odd ratios (OR) of leucopenia/neutropenia in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex when the 3 trials were pooled.




Test for heterogeneity for the interaction term: $p = 0.81$

Overall treatment-by-gender interaction : $p = 0.43$

The Odd Ratios (ORs) given on the right side represent the OR of the treatment-by-sex interaction ($OR_{Cyclo/Ifo \text{ in males}} / OR_{Cyclo/Ifo \text{ in females}}$) estimated independently for each trial and in the pooled dataset, using the logistic regression model, stratified by trial and sex, and including treatment (cyclophosphamide vs. ifosfamide) and age (< 12, 12-18, and >18 years) as the main fixed effects. Heterogeneity of the interaction (treatment x sex) across trials was assessed using the 3-order interaction term.


Supplemental Figure S6: Forest plot of the odd ratios (OR) of infection in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex when the 3 trials were pooled.



Test for heterogeneity for the interaction term: p= 0.12

Overall treatment-by-gender interaction : p=0.65

Supplemental Figure S7: Forest plot of the odd ratios (OR) of renal toxicity in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex when the 3 trials were pooled.



Test for heterogeneity for the interaction term: $p = 0.19$

Overall treatment-by-gender interaction : $p = 0.19$

3. Description of the randomized controlled trials comparing alkylating agents, not included in the meta-analysis

Supplemental Table S2: Information extracted from the 3 randomized trials conducted in women and not included in the meta-analysis

Author	Pathology	Treatment arms	Number of patients	Response rate (CR or PR)	Progression-free survival (PFS) [‡]			Overall survival (OS)
Buzdar [28]	Breast carcinoma	FAC+BCG+levamisole	117	72.6%	Median time to progression: 17 months			Median OS: 21.4 months
		FAI+BCG+levamisole	49*	65.3%	Median time to progression: 17.8 months			Median OS: 23.5 months
Nishida [29]	Ovarian epithelial cancer	PAC	53	NA	3y-PFS: 84.9%	5y-PFS: 79.0%	10y-PFS: 67.8%	NA
		PAI	52	NA	3y-PFS: 88.5%	5y-PFS: 88.5%	10y-PFS: 81.1%	NA
Pawinski [30]	Adenocarcinoma of uterine corpus	Cyclo	29	6.9%	Median time to progression: 7 weeks			NA
		Ifo	32	12.5%	Median time to progression: 8 weeks			NA

FAC: 5-fluorouracil, adriamycin, cyclophosphamide, FAI: 5-fluorouracil, adriamycin, cyclophosphamide, PAC: cisplatin, epirubicin, cyclophosphamide, PAI: cisplatin, epirubicin, ifosfamide, Cyclo: cyclophosphamide, Ifo: ifosfamide, CR: complete response, PR: partial response, NA: not available

* The FAI arm was closed because of increased bladder toxicity observed with ifosfamide resulting in a greater number of patients in the FAC arm.

‡: no information on the precision of the estimate (standard error, confidence interval or number of at-risk patients) was reported.